Stifel Upgrades Verve Therapeutics to Buy, Raises Price Target to $56
Stifel analyst Dae Gon Ha upgrades Verve Therapeutics (NASDAQ:VERV) from Hold to Buy and raises the price target from $32 to $56.
B of A Securities Upgrades Getty Realty to Neutral
B of A Securities analyst Joshua Dennerlein upgrades Getty Realty (NYSE:GTY) from Underperform to Neutral.
B of A Securities Upgrades Essential Props Realty to Buy
B of A Securities analyst Joshua Dennerlein upgrades Essential Props Realty (NYSE:EPRT) from Neutral to Buy.
Truist Securities Upgrades Centennial Resource Dev to Buy
Truist Securities analyst Neal Dingmann upgrades Centennial Resource Dev (NASDAQ:CDEV) from Hold to Buy.
Wolfe Research Upgrades AvalonBay Communities to Outperform
Wolfe Research analyst Andrew Rosivach upgrades AvalonBay Communities (NYSE:AVB) from Peer Perform to Outperform.
Why This Denny’s Analyst Is Turning Bullish
There is an upside to Denny's Corp.’s (NASDAQ: DENN) current expectations for the back half of 2022 and 2023, while the company’s long-term prospects remain intact under new CEO Kelli Valade, according to Wedbush.
William Blair Upgrades Foot Locker to Hold, Announces $29 Price Target
William Blair analyst Sam Poser upgrades Foot Locker (NYSE:FL) from Sell to Hold and announces $29 price target.